PURPOSE: To evaluate the efficacy of desmopressin on nocturia, quality of sleep (QoS), and health-related quality of life (HRQoL) in men with lower urinary tract symptoms suggestive of benign prostatic hyperplasia (LUTS/BPH) and nocturia due to nocturnal polyuria (NP) as the predominant symptom. METHODS: A German observational, multicenter, post-marketing surveillance study including men with LUTS/BPH and nocturia due to NP starting 3 months of desmopressin treatment. RESULTS: In total, 137 patients with a mean of 3.8 nocturnal voids (range 2-7) were included. Desmopressin significantly reduced the mean number of nocturnal voids by 53 %, mean IPSS nocturia question by 50 %, and the mean ratio of night/24-h urine volume by 39 % from baseline to endpoint. The hours of undisturbed sleep significantly increased by 74 %; 71 % of men reported about undisturbed sleep of ≥4 h at study end. Additionally, there was a significant reduction in the Leeds Sleep Evaluation Questionnaire score, indicating a clinically relevant QoS improvement. This was associated with an improved HRQoL, as shown by a significant improvement in both the mean IPSS-QoL question by 43 % and mean ICIQ-N nocturia problem question by 53 %. Concomitant alpha-blocker use had no effect on the efficacy of desmopressin. The incidence of adverse events was low (2.2 %). Hyponatremia was not observed in any patient. The majority of patients and physicians rated the efficacy and tolerability of desmopressin as good/very good. CONCLUSIONS: Desmopressin is an effective and well-tolerated treatment for nocturia due to NP in patients with LUTS/BPH in daily practice under routine conditions.
PURPOSE: To evaluate the efficacy of desmopressin on nocturia, quality of sleep (QoS), and health-related quality of life (HRQoL) in men with lower urinary tract symptoms suggestive of benign prostatic hyperplasia (LUTS/BPH) and nocturia due to nocturnal polyuria (NP) as the predominant symptom. METHODS: A German observational, multicenter, post-marketing surveillance study including men with LUTS/BPH and nocturia due to NP starting 3 months of desmopressin treatment. RESULTS: In total, 137 patients with a mean of 3.8 nocturnal voids (range 2-7) were included. Desmopressin significantly reduced the mean number of nocturnal voids by 53 %, mean IPSS nocturia question by 50 %, and the mean ratio of night/24-h urine volume by 39 % from baseline to endpoint. The hours of undisturbed sleep significantly increased by 74 %; 71 % of men reported about undisturbed sleep of ≥4 h at study end. Additionally, there was a significant reduction in the Leeds Sleep Evaluation Questionnaire score, indicating a clinically relevant QoS improvement. This was associated with an improved HRQoL, as shown by a significant improvement in both the mean IPSS-QoL question by 43 % and mean ICIQ-N nocturia problem question by 53 %. Concomitant alpha-blocker use had no effect on the efficacy of desmopressin. The incidence of adverse events was low (2.2 %). Hyponatremia was not observed in any patient. The majority of patients and physicians rated the efficacy and tolerability of desmopressin as good/very good. CONCLUSIONS: Desmopressin is an effective and well-tolerated treatment for nocturia due to NP in patients with LUTS/BPH in daily practice under routine conditions.
Authors: Philip van Kerrebroeck; Paul Abrams; David Chaikin; Jenny Donovan; David Fonda; Simon Jackson; Poul Jennum; Theodore Johnson; Gunnar Lose; Anders Mattiasson; Gary Robertson; Jeff Weiss Journal: Neurourol Urodyn Date: 2002 Impact factor: 2.696
Authors: Matthias Oelke; Claus G Roehrborn; Carlos D'Ancona; Timothy H Wilson; Ramiro Castro; Michael Manyak Journal: World J Urol Date: 2014-06-06 Impact factor: 4.226
Authors: Philip van Kerrebroeck; Masoumeh Rezapour; Ariane Cortesse; Joachim Thüroff; Anders Riis; Jens Peter Nørgaard Journal: Eur Urol Date: 2007-01-16 Impact factor: 20.096
Authors: M J Schnabel; W Brummeisl; M Burger; J J Rassweiler; T Knoll; A Neisius; C G Chaussy; H M Fritsche Journal: Urologe A Date: 2015-09 Impact factor: 0.639
Authors: Matthias Oelke; Erika Adler; Daniela Marschall-Kehrel; Thomas R W Herrmann; Richard Berges Journal: World J Urol Date: 2014-10 Impact factor: 4.226